NCT07417111 Continued Pressure for Alveolar Protection (CPAP Trial)
| NCT ID | NCT07417111 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NICHD Neonatal Research Network |
| Condition | Bronchopulmonary Dysplasia (BPD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 860 participants |
| Start Date | 2026-11-05 |
| Primary Completion | 2028-11-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 860 participants in total. It began in 2026-11-05 with a primary completion date of 2028-11-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the CPAP Trial is to test whether extending CPAP until 34 weeks' PMA or for at least 2 additional weeks compared to weaning to a nasal canula will decrease the likelihood of bronchopulmonary dysplasia or death at 36 weeks' PMA.
Eligibility Criteria
Inclusion Criteria: * Gestational age \<29 weeks at birth * PMA \<32 weeks at study entry * On treatment with CPAP without a rate in FiO2 \<0.25 and PEEP of 4-5 cmH2O * Meet stability criteria: * If previously intubated must be extubated ≥ 72 hours * \<3 self-resolving apneas (≤ 20 s) and/or bradycardia (\<100 bpm) in any hour over previous 6 hours * No episodes of apnea or bradycardia requiring intervention (oxygen/stimulation/bag and mask) for 24 hours * Parents/legal guardians consent for enrollment Exclusion Criteria: * Major malformation * Neuromuscular condition that affects respiration * Terminal illness * Decision to withhold or limit support * Too sick to participate in opinion of Attending physician * Clinical shock, sepsis * Planned surgery during study period
Contact & Investigator
Colm P. Travers, MD
PRINCIPAL INVESTIGATOR
University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT07417111 clinical trial?
This trial is open to participants of all sexes, up to 31 Weeks, studying Bronchopulmonary Dysplasia (BPD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07417111 currently recruiting?
Yes, NCT07417111 is actively recruiting participants. Contact the research team at cptravers@uabmc.edu for enrollment information.
Where is the NCT07417111 trial being conducted?
This trial is being conducted at Birmingham, United States, Palo Alto, United States, San Diego, United States, Atlanta, United States and 11 additional locations.
Who is sponsoring the NCT07417111 clinical trial?
NCT07417111 is sponsored by NICHD Neonatal Research Network. The principal investigator is Colm P. Travers, MD at University of Alabama at Birmingham. The trial plans to enroll 860 participants.